Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; Phase 2 planned Q1 2026

Corvus Pharmaceuticals, Inc.

Cohort 4: 75% of soquelitinib patients achieved EASI 75 vs 20% placebo; 25% achieved EASI 90 vs 0% placebo.
Mean EASI reduction at day 56: 72% for soquelitinib vs 40% for placebo; separation statistically significant (p=0.035).
No new safety signals; AE rates 41.7% soquelitinib vs 50% placebo, all Grade 1-2, no dose modifications.
Activity seen in patients with prior systemic therapy including dupilumab/JAK inhibitors.
Plans to initiate Phase 2 trial in moderate-to-severe atopic dermatitis in Q1 2026 (approx. 200 patients, 4 arms).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.